Gene Expression Signatures to Predict Treatment Response in Systemic Sclerosis
预测系统性硬化症治疗反应的基因表达特征
基本信息
- 批准号:8931885
- 负责人:
- 金额:$ 85.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-06 至 2017-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAlgorithmsArchivesAutoantibodiesAutoimmune DiseasesBiochemical PathwayBioinformaticsBiological MarkersBiopsyCellceptClassificationClinicalClinical Course of DiseaseClinical TrialsDNA Microarray ChipDevelopmentDiagnosisDiagnosticDiseaseEnrollmentEtiologyExposure toFibrosisFreezingGene ExpressionGene Expression ProfileGene Expression ProfilingGenesGleevecGoalsGoldHealthHeartHereditary DiseaseHeterogeneityImatinib mesylateImmunosuppressive AgentsIndividualInflammatoryLaboratoriesLungMapsMeasuresMolecularMolecular ProfilingNatureObservational StudyOrganOutcomeOutcome MeasureParaffin EmbeddingPathogenesisPathway interactionsPatient SelectionPatientsPharmaceutical PreparationsPharmacologic SubstancePhasePhysiciansPilot ProjectsPublishingRelative (related person)Research DesignRiskSamplingSclerodermaServicesSignal PathwaySkinSystemic SclerodermaTestingTranslatingTyrosine Kinase InhibitorValidationWorkbaseclinical phenotypecohortcostdesigndrug developmenteffective therapyeffectiveness trialefficacy trialimprovedindividualized medicineinsightlymphocyte proliferationmalignant breast neoplasmmycophenolate mofetilnano-stringnovelnovel diagnosticsopen labelpatient populationprospectiveresearch clinical testingresponserisk benefit ratiostandard of caretargeted treatmenttechnology developmenttooltreatment planningtreatment responsevascular abnormality
项目摘要
DESCRIPTION (provided by applicant): Today, systemic sclerosis (SSc) clinical trials generally include all subsets; some may benefit, others do not, confounding measures of efficacy. Because each expression subset has a different underlying deregulated molecular pathway, no single drug is expected to benefit all patients i.e. rational patient selection is required to facilitate drug development. Further, a quantitative measure of clinical outcome and endpoints will enable a scientific measure of trial effectiveness and avoid the difficulties associated with the cyclic nature of SSc. For example, response to imatinib mesylate (Gleevec(R)), a tyrosine kinase inhibitor and to mycophenolate mofetil (Cellcept), an attenuator of lymphocyte proliferation, can be quantitatively measured by gene expression. Finally, insights into the molecular pathways defining each subtype will enable us to identify and potentially design new drugs. Beyond drug development, subtyping will help individual patients and their doctors by allowing an individualized treatment plan informed by each patient's subtype. Together, these benefits are both exciting and compelling, and are fundamentally changing what it means to be diagnosed with SSc. This work will provide insights into the pathogenesis of the disease that may influence the development of new treatments by other groups or pharmaceutical companies. The immediate result of this study is the validation and prospective clinical testing of gene expression biomarkers on a new platform for predicting treatment response in SSc. Development of this technology into a clinical diagnostic tool and service will significantly improve the management and ultimately the health of patients with SSc.
描述(由申请人提供):今天,系统性硬化症(SSC)临床试验通常包括所有子集;有些人可能受益,另一些人则不会使效力的措施混淆。由于每个表达子集都有不同的潜在放松管制分子途径,因此没有任何一种药物受益于所有患者,即需要理性的患者选择以促进药物发育。此外,对临床结局和终点的定量度量将实现科学的试验效率度量,并避免与SSC的环状性质相关的困难。例如,可以通过基因表达来定量测量酪氨酸激酶抑制剂(gleevec(r)),一种酪氨酸激酶抑制剂(gleevec(r)),对淋巴细胞增殖的衰减剂(Cellcept)的反应。最后,对定义每个亚型的分子途径的见解将使我们能够识别并可能设计新药。除了药物开发外,亚型还将通过允许每个患者的亚型告知个性化治疗计划来帮助个别患者及其医生。这些好处共同令人兴奋和引人注目,并且从根本上改变了被诊断为SSC的含义。这项工作将为疾病的发病机理提供见解,这可能影响其他群体或制药公司的新疗法发展。这项研究的直接结果是对基因表达生物标志物的验证和前瞻性临床测试,用于预测SSC治疗反应的新平台。将该技术开发为临床诊断工具和服务将显着改善SSC患者的管理和健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL W FANGER其他文献
MICHAEL W FANGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL W FANGER', 18)}}的其他基金
Therapy of transplantation-induced oxidative injury using polymeric antioxidants
使用聚合抗氧化剂治疗移植引起的氧化损伤
- 批准号:
8951662 - 财政年份:2015
- 资助金额:
$ 85.49万 - 项目类别:
Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system
利用 CRISPR/Cas 系统的组件破坏 HIV-1 原病毒
- 批准号:
8659862 - 财政年份:2014
- 资助金额:
$ 85.49万 - 项目类别:
Therapy of transplantation-induced oxidative injury using polymeric antioxidants
使用聚合抗氧化剂治疗移植引起的氧化损伤
- 批准号:
8780189 - 财政年份:2014
- 资助金额:
$ 85.49万 - 项目类别:
Combination immunotherapies for the treatment of melanoma
用于治疗黑色素瘤的联合免疫疗法
- 批准号:
8453586 - 财政年份:2013
- 资助金额:
$ 85.49万 - 项目类别:
Preclinical Development of a Novel Plaque-Regressing Therapy For Atherosclerosis
新型斑块消退疗法治疗动脉粥样硬化的临床前开发
- 批准号:
8394110 - 财政年份:2012
- 资助金额:
$ 85.49万 - 项目类别:
Scleroderma Subtyping from Fresh and Archived Biopsies using NextGen Sequencing
使用 NextGen 测序从新鲜和存档的活检中进行硬皮病亚型分析
- 批准号:
8200724 - 财政年份:2011
- 资助金额:
$ 85.49万 - 项目类别:
Development of a Novel Anti-Inflammatory Therapeutic Based on Antithrombin
基于抗凝血酶的新型抗炎治疗药物的开发
- 批准号:
8058061 - 财政年份:2011
- 资助金额:
$ 85.49万 - 项目类别:
Gene Expression Signatures to Predict Treatment Response in Systemic Sclerosis
预测系统性硬化症治疗反应的基因表达特征
- 批准号:
8834415 - 财政年份:2011
- 资助金额:
$ 85.49万 - 项目类别:
ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial
ChNKG2D 靶向细胞癌症治疗:I 期临床试验
- 批准号:
8394167 - 财政年份:2010
- 资助金额:
$ 85.49万 - 项目类别:
相似国自然基金
分布式非凸非光滑优化问题的凸松弛及高低阶加速算法研究
- 批准号:12371308
- 批准年份:2023
- 资助金额:43.5 万元
- 项目类别:面上项目
资源受限下集成学习算法设计与硬件实现研究
- 批准号:62372198
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于物理信息神经网络的电磁场快速算法研究
- 批准号:52377005
- 批准年份:2023
- 资助金额:52 万元
- 项目类别:面上项目
考虑桩-土-水耦合效应的饱和砂土变形与流动问题的SPH模型与高效算法研究
- 批准号:12302257
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向高维不平衡数据的分类集成算法研究
- 批准号:62306119
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Genomic marker to distinguish aggressive and indolent prostate cancer
区分侵袭性和惰性前列腺癌的基因组标记
- 批准号:
10820859 - 财政年份:2023
- 资助金额:
$ 85.49万 - 项目类别:
A novel data-driven approach for personalizing smoking cessation pharmacotherapy
一种新的数据驱动的个性化戒烟药物治疗方法
- 批准号:
10437438 - 财政年份:2022
- 资助金额:
$ 85.49万 - 项目类别:
A novel data-driven approach for personalizing smoking cessation pharmacotherapy
一种新的数据驱动的个性化戒烟药物治疗方法
- 批准号:
10578721 - 财政年份:2022
- 资助金额:
$ 85.49万 - 项目类别:
Using Second Harmonic Generation to Predict Metastatic Outcome in Colon Adenocarcinoma
使用二次谐波生成预测结肠腺癌的转移结果
- 批准号:
9314660 - 财政年份:2017
- 资助金额:
$ 85.49万 - 项目类别:
Effects of air pollution and gestational diabetes on autism
空气污染和妊娠糖尿病对自闭症的影响
- 批准号:
9524935 - 财政年份:2017
- 资助金额:
$ 85.49万 - 项目类别: